DCSIMG

© 2010, Bayer Schering Pharma AG
This website is intended to provide information to an international audience outside the USA and UK.
Last updated on 9th March 2010

Xarelto®: Simple, Uncomplicated Clot Prevention

Xarelto® is indicated for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.1

Health economics

Thromboprophylaxis with Xarelto® compared to enoxaparin can result in significant cost savings per patient, with marked cost savings for health care systems.13

Superior efficacy in clot prevention compared to enoxaparin, with comparable safety

The RECORD programme found Xarelto® to offer superior efficacy with a similar and low level of bleeding compared to enoxaparin in preventing VTE in adult patients undergoing elective hip or knee replacement surgery.2, 3, 4

Reassuring and comparable safety

In the RECORD programme each separate study found Xarelto® to have a reassuring safety profile in a wide range of patients, with data comparable to that of enoxaparin.2, 3, 4

Xarelto® in practice Q&A

Answers to commonly asked questions about Xarelto®

For the patient

Help patients understand the risks of VTE and the advantages of preventive therapy.

Convenience with simplified dosing

With one tablet once daily at a fixed dose, Xarelto® provides simple, uncomplicated clot prevention regardless of patient gender, age, or weight, without the need for routine coagulation monitoring.1, 2, 3, 4
  • 1 - Xarelto® (rivaroxaban) Summary of Product Characteristics as approved by the European Commission.
  • 13 - Lees M, Sengupta N. Economic impact of venous thromboembolism prophylaxis with rivaroxaban after major orthopaedic surgery. Poster P082 presented at: 20th International Congress on Thrombosis (ICT), June 25-28, 2008; Athens, Greece.
  • 2 - Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
  • 3 - Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39.
  • 4 - Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
Venous thromboembolism
A disease process beginning with a blood clot occurring within the venous system, including deep vein thrombosis and pulmonary embolism.
Thromboprophylaxis
Preventative treatment for blood clotting.
Efficacy
The ability of a drug to produce the desired effect.